Molecular Tumor Board: 65-year-old male with recurrent hepatocellular carcinoma

In this molecular tumor board, our Medical Affairs Team presents a case of recurrent hepatocellular carcinoma (HCC) with interesting immune phenotypes discovered on a comprehensive genomic and immune profiling test. We reviewed TIGIT as a promising target for cancer immunotherapy and outlined the prognosis and treatment paradigm of HCC along with discussing the different stages and potential barriers of clinical trial enrollment.

Molecular Tumor Board: 44-year-old male with advanced NSCLC and ROS1 fusion

This Molecular Tumor Board, our Oncology Medical Affairs team reviews concurrent tissue- and plasma-based comprehensive NGS testing for the management of a young patient with advanced stage NSCLC. A growing number of guideline-recommended biomarkers are reviewed for frontline targeted therapy selection and prevalence of oncogenic driver alterations in NSCLC. The process of utilizing and optimizing cytology specimens for NGS analysis is also discussed.

<span>Chromosomal Aberration Assay: Unraveling the genetic puzzle to evaluate medical device safety through genetic toxicology</span>
April 15, 2024

Chromosomal Aberration Assay: Unraveling the genetic puzzle to evaluate medical device safety through genetic toxicology

Medical devices play a crucial role in the healthcare industry, and ensuring their safety is paramount to human health. Genotoxicity assessment, also known as genetox testing, is an essential aspect of medical device development. In the evolving landscape of medical devices, Labcorp’s Chromosomal Aberration Assay plays an important role in the assessment of genotoxic potential of these devices, evaluating their safety at a chromosomal level. Let’s explore the significance of this assay and how this powerful tool can assess potential risks associated with medical devices and human health.
April 11, 2024

Labcorp Declares Quarterly Dividend

BURLINGTON, N.C. , April 11, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 12, 2024 , to